A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Recruiting now · Phase 1/Phase 2

Conditions studied: Advanced Neuroendocrine Carcinoma

In brief

An open-label, multicenter phase Ib/II clinical study to evaluate the safety and efficacy of LBL-024 combined with etoposide and platinum in the first-line treatment of patients with advanced neuroendocrine carcinoma (NEC)

Key facts

Study ID

NCT06157827

Run by

Nanjing Leads Biolabs Co.,Ltd

People needed

178

Starts

2023-12-08

Expected to finish

2027-03-28

Last updated by the study team

2026-03-12

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Agree to follow the trial treatment regimen and visit schedule, voluntarily enroll, and sign the written informed consent.
• aged 18-75 years (including borderline values) at the time of signing the informed consent form
• The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1.
• The expected survival time is at least 12 weeks.
• According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours），the subjects enrolled have at least one measurable target lesion.
• Fertile men and women of childbearing age are willing to take effective contraceptive measures from the signing of the informed consent form to 6 months after the last dose of the investigational drug; women of childbearing age include premenopausal women and women who had menopause less than two years ago. Blood pregnancy test results must be negative for women of childbearing age within 7 days prior to the initial dose of the investigational drug.

You may not qualify if…

• Subjects who underwent major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks prior to the initial use of the investigational drug, or require elective surgery during the trial period
• Use of immunomodulatory drugs within 14 days prior to the initial use of the investigational drug, including but not limited to thymosin, interleukin, and interferon
• Subjects with an active infection that currently requires intravenous anti-infective therapy.
• Clinically uncontrollable pleural effusion, pericardial effusion, and requiring repeated drainage or medical intervention.
• medical history of immunodeficiency including HIV antibody positive.
• Pregnant or lactating women.
• The investigator believes that the subject has other conditions that may affect compliance or that are not suitable for participating in this study.

Where it is running

• Anhui Provincial Hospital — Hefei, Anhui, China (enrolling)
• Anhui Cancer Hospital — Hefei, Anhui, China (enrolling)
• Beijing GoBroad Hospital — Beijing, Beijing Municipality, China (enrolling)
• Beijing Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)
• Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality, China (enrolling)
• Fujian Cancer Hospital — Fuzhou, Fujian, China (enrolling)
• Sun Yat-sen University Cancer Center (SYSUCC) — Guangzhou, Guangdong, China (enrolling)
• The First Affiliated Hospital of Guangdong Pharmaceutical University — Guangzhou, Guangdong, China (enrolling)
• Guangxi Medical University Cancer Hospital — Nanning, Guangxi, China (enrolling)
• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China (enrolling)
• The First Affiliated Hospital of Henan University of Science and Technology — Luoyang, Henan, China (enrolling)
• Henan Cancer Hospital — Zhengzhou, Henan, China (enrolling)
• Hubei Cancer Hospital — Wuhan, Hubei, China (enrolling)
• Xiangyang Central Hospital — Xiangyang, Hubei, China (enrolling)
• The First Affiliated Hospital of Nanchang University — Nanchang, Jiangxi, China (enrolling)
• Liaoning Cancer Hospital — Shenyang, Liaoning, China (enrolling)
• Qilu Hospital of Shandong University — Jinan, Shandong, China (enrolling)
• Shandong Cancer Hospital — Jinan, Shandong, China (enrolling)
• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (enrolling)
• Shanxi Cancer hospital — Taiyuan, Shanxi, China (enrolling)
• West China Hospital of Sichuan University — Chengdu, Sichuan, China (enrolling)
• The First Affiliated Hospital Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (enrolling)
• The Second Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (enrolling)
• Sir Run Run Shaw Hospital，Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (enrolling)
• Zhejiang Cancer Hospital — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.